Dr. Nicolas Huot: “Predicting the exact timeline for the widespread implementation of therapies involving the reprogramming of Natural Killer cells for HIV prevention and treatment is challenging”
Nicolas Huot is a postdoc fellow in Dr. M.Müller-Trutwin Lab at the pasteur institut in PARIS , studying the role of NK cells in secondary lymphoid tissues [...]
Vicente Planelles: “Research in the field of senotherapeutics is still in its early stages, but initial results in the area of aging are highly encouraging”
Vicente Planelles, PhD, is a Professor in the Department of Pathology at the University of Utah and a member of the Cell Response and Regulation Program at [...]
Dr. Jean Michel – Molina: “For biomedical prevention of HIV we have a number of drugs which are likely to be available in the future: long acting drugs for prevention”
Jean-Michel Molina is Professor of Infectious Diseases at the University of Paris Diderot - Paris 7, France, and Head of the Infectious Diseases Department at the Saint-Louis [...]
Dra. Katharine Barr: “There are recent discoveries that support the development of new cure strategies”.
La Dra. Katharine Barr, quien participa en la sesión inaugural, nos habla sobre el reservorio del VIH y otras cuestiones relacionadas con los últimos avances y descubrimientos. [...]
Dr. Paul E. Sax: «We should continue to search for a cure as an aspirational goal”
El Dr. Paul Sax participa en la sesión inaugural del XIV Congreso de GeSIDA, con una ponencia titulada 'HAART, ART, 2DR, LA-ART.... What acronym is next?'. Nos [...]
Entrevista al Dr. Brad Jones, del Weill Cornell Medicine
El Dr. Brad Jones, del Weill Cornell Medicine de Nueva York, será el encargado de abrir la tercera jornada del XIII Congreso Nacional de GeSIDA con una [...]